US FTC seeks additional info on Pfizer’s proposed takeover of Seagen By Reuters

[ad_1]

2/2

© Reuters. FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo/File Photo

2/2

(Reuters) -The US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer (NYSE:)’s proposed acquisition of Seagen Inc, Seagen said on Friday.

The antitrust agency sent the requests separately to both the companies, a regulatory filing said.

Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs.

The recent scrutiny by the antitrust agency to block Amgen (NASDAQ:)’s $27.8 billion deal to buy Horizon Therapeutics (NASDAQ:) has made investors jittery around the Pfizer-Seagen deal as well.

Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing.

[ad_2]

Source link

2/2

© Reuters. FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo/File Photo

2/2

(Reuters) -The US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer (NYSE:)’s proposed acquisition of Seagen Inc, Seagen said on Friday.

The antitrust agency sent the requests separately to both the companies, a regulatory filing said.

Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs.

The recent scrutiny by the antitrust agency to block Amgen (NASDAQ:)’s $27.8 billion deal to buy Horizon Therapeutics (NASDAQ:) has made investors jittery around the Pfizer-Seagen deal as well.

Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing.

Add a Comment

Your email address will not be published. Required fields are marked *